title: Oral chelation: should it be used with young children?
abstract: Deferasirox, the only oral iron chelator approved in the US and Canada, achieved a pediatric label indication down to 2 years of age. FDA-mandated post-marketing safety surveillance in children under age 6 is ongoing. We wish to raise a non-safety-related concern with deferasirox chelation in very young children (2-5 years old). Specifically, the circumstances required for reliable daily ingestion of deferasirox do not mesh well with the developmental characteristics common in young children, which may limit adherence and cause parental distress. We review developmental challenges associated with oral chelation in this age group and provide suggestions to improve adherence in this population.
authors.affiliation: Department of Psychiatry, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA. Lauren.mednick@childrens.harvard.edu
authors.forename: Lauren M
authors.initials: LM
authors.lastname: Mednick
authors.forename: Jennifer
authors.initials: J
authors.lastname: Braunstein
authors.forename: Ellis
authors.initials: E
authors.lastname: Neufeld
mesh_terms: D001565:Benzoates / Q000627:therapeutic use*; D002675:Child, Preschool; D000077588:Deferasirox; D011307:Drug Prescriptions; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D055118:Medication Adherence; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox